Thrombolytic agents derived from streptokinase

Details Thrombolytic agents derived from streptokinase Thrombolytic agents derived from streptokinase

Category

C - Chemistry, Metallurgy

Subcategory

12

Subsubcategory

N

IPC codes

C12N 9/00 (2006.01) A61K 38/16 (2006.01) A61K 38/17 (2006.01) C07K 14/315 (2006.01) A61K 38/00 (2006.01)

Type

Patent

Patent number

CA 2327526

Description

Structural information about the streptokinase-micro plasminogen complex has been used to identify the part of the streptokinase structure not involved in plasminogen complexation or activation. These nonessential portions can be modified to reduce antigenicity, for example, by changing the nonessential portions of streptokinose to more human-like polypeptide portions ("humanization of streptokinase"). One way this can be done is to compare the nonessential portion to a structural database of human proteins to find similar structures. Then the streptokinase nonessential structural part is replaced with the human structural part such as by genetic engineering of a mutant encoding the individual streptokinases, which is then expressed in a bacterial host such as E. coli. Alternatively, the nonessential portions can be removed or truncated to simplify streptokinase to a smaller molecule which retains plasminogen activation activity. Such smaller proteins should have reduced antigenicity and be cheaper and easier to produce. The modified streptokinases are useful in treating clotting disorders.

Des données de structure relatives au complexe streptokinase/micro-plasminogène ont permis d'identifier la partie de la structure de la streptokinase qui n'intervient pas dans la complexation ou l'activation du plasminogène. Il est possible de modifier ces parties non essentielles de façon à réduire l'antigénicité, en transformant par exemple les parties non essentielles de la streptokinase en parties polypeptidiques d'origine apparemment humaine (? humanisation de la streptokinase ?). Pour ce faire, on peut comparer la partie non essentielle à une base de données structurelles de protéines humaines afin d'identifier des structures similaires. On remplace ensuite la partie structurelle non essentielle de la streptokinase par la partie structurelle humaine, par exemple en manipulant génétiquement un mutant codant pour les streptokinases individuelles, qui est ensuite exprimé dans un hôte bactérien tel que E. coli. Il est également possible de retirer ou de supprimer les parties non essentielles pour simplifier la streptokinase en la transformant en une molécule plus petite qui conserve l'activité d'activation du plasminogène. Ces petites molécules possèdent une antigénicité réduite et peuvent être produites plus facilement et de manière peu onéreuse. Les streptokinases modifiées s'avèrent utiles au traitement des troubles de la coagulation.

Affiliated with

Also associated with

Rating

Thrombolytic agents derived from streptokinase does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Thrombolytic agents derived from streptokinase, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thrombolytic agents derived from streptokinase will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1688250